Media coverage about Biolase (NASDAQ:BIOL) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biolase earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the medical technology company an impact score of 44.8085393749219 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Biolase (NASDAQ BIOL) traded down $0.01 on Monday, reaching $0.44. 54,200 shares of the company’s stock traded hands, compared to its average volume of 167,314. The firm has a market cap of $32.71, a PE ratio of -1.33 and a beta of 2.30. Biolase has a 12 month low of $0.28 and a 12 month high of $1.87.

Separately, ValuEngine raised shares of Biolase from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.

In other news, major shareholder Larry N. Feinberg acquired 12,545,615 shares of the company’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average cost of $0.43 per share, with a total value of $5,394,614.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at

Biolase Company Profile

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Insider Buying and Selling by Quarter for Biolase (NASDAQ:BIOL)

Receive News & Ratings for Biolase Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase and related companies with Analyst Ratings Network's FREE daily email newsletter.